Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease.

Lee J, Hwang YJ, Shin JY, Lee WC, Wie J, Kim KY, Lee MY, Hwang D, Ratan RR, Pae AN, Kowall NW, So I, Kim JI, Ryu H.

Acta Neuropathol. 2013 May;125(5):727-39. doi: 10.1007/s00401-013-1103-z. Epub 2013 Mar 2.


Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease.

Lee J, Hwang YJ, Kim Y, Lee MY, Hyeon SJ, Lee S, Kim DH, Jang SJ, Im H, Min SJ, Choo H, Pae AN, Kim DJ, Cho KS, Kowall NW, Ryu H.

Acta Neuropathol. 2017 Jun 7. doi: 10.1007/s00401-017-1732-8. [Epub ahead of print]


ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease.

Lee J, Hong YK, Jeon GS, Hwang YJ, Kim KY, Seong KH, Jung MK, Picketts DJ, Kowall NW, Cho KS, Ryu H.

Cell Death Differ. 2012 Jul;19(7):1109-16. doi: 10.1038/cdd.2011.196. Epub 2012 Jan 13.


Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I.

Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010. Epub 2008 Apr 16.


The Role of H3K4me3 in Transcriptional Regulation Is Altered in Huntington's Disease.

Dong X, Tsuji J, Labadorf A, Roussos P, Chen JF, Myers RH, Akbarian S, Weng Z.

PLoS One. 2015 Dec 4;10(12):e0144398. doi: 10.1371/journal.pone.0144398. eCollection 2015.


HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.

Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME.

Hum Mol Genet. 2005 Oct 1;14(19):2871-80. Epub 2005 Aug 22.


Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.

Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P.

J Neurochem. 2001 Aug;78(4):694-703.


Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.

Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, Lopez E, Myers RH, MacDonald ME, Wheeler VC.

Hum Mol Genet. 2006 Jun 15;15(12):2015-24. Epub 2006 May 10.


Mechanisms of disease: Histone modifications in Huntington's disease.

Sadri-Vakili G, Cha JH.

Nat Clin Pract Neurol. 2006 Jun;2(6):330-8. Review.


Epigenetic mechanisms of neurodegeneration in Huntington's disease.

Lee J, Hwang YJ, Kim KY, Kowall NW, Ryu H.

Neurotherapeutics. 2013 Oct;10(4):664-76. doi: 10.1007/s13311-013-0206-5. Review.


Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.

Glajch KE, Sadri-Vakili G.

J Huntingtons Dis. 2015;4(1):1-15. doi: 10.3233/JHD-159001. Review.


Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.


Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.

Choudhury KR, Das S, Bhattacharyya NP.

J Proteomics. 2016 Jan 30;132:155-66. doi: 10.1016/j.jprot.2015.11.007. Epub 2015 Nov 12.


In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Thomas EA, Coppola G, Tang B, Kuhn A, Kim S, Geschwind DH, Brown TB, Luthi-Carter R, Ehrlich ME.

Hum Mol Genet. 2011 Mar 15;20(6):1049-60. doi: 10.1093/hmg/ddq548. Epub 2010 Dec 20.


Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.

Sun Z, Wang HB, Deng YP, Lei WL, Xie JP, Meade CA, Del Mar N, Goldowitz D, Reiner A.

Neurobiol Dis. 2005 Dec;20(3):907-17. Epub 2005 Jun 28.


Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.

Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ.

J Neurosci. 2000 Jul 1;20(13):5115-23.


Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease.

van Roon-Mom WM, Pepers BA, 't Hoen PA, Verwijmeren CA, den Dunnen JT, Dorsman JC, van Ommen GB.

BMC Mol Biol. 2008 Oct 9;9:84. doi: 10.1186/1471-2199-9-84.


Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Desplats PA, Lambert JR, Thomas EA.

Neurobiol Dis. 2008 Sep;31(3):298-308. doi: 10.1016/j.nbd.2008.05.005. Epub 2008 May 22.


Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease.

Wang F, Yang Y, Lin X, Wang JQ, Wu YS, Xie W, Wang D, Zhu S, Liao YQ, Sun Q, Yang YG, Luo HR, Guo C, Han C, Tang TS.

Hum Mol Genet. 2013 Sep 15;22(18):3641-53. doi: 10.1093/hmg/ddt214. Epub 2013 May 12.


Modulation of nucleosome dynamics in Huntington's disease.

Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, Smith K, Ryu H, Ferrante RJ.

Hum Mol Genet. 2007 May 15;16(10):1164-75. Epub 2007 Apr 2.


Supplemental Content

Support Center